

# Employee Benefits Division

# Cell and Gene Therapy Policy

May 2026 - ASE/PSE Commission

Move all Cell and Gene Therapy to “excluded” on the medical benefit so that it may only be reviewed on appeal to EBD. This policy update helps to keep tight control on high cost drugs with complicated pricing agreements.

	Cell (CAR-T) or Gene Therapy	Drug	Treating Diagnosis	Recommendation	Cost (AWP)	Impacted members	Change
1	Cell	Abecma (idecatagene)	Relapsed/refractory multiple myeloma	Exclude	\$419,500	0	No EBRx Restrictions to Exclude
2	Gene	Adstiladrin (nadofaragene)	High risk BCG unresponsive non-muscle invasive bladder cancer	Exclude	\$195,000	0	
3	Cell	Amtagvi (lifileucel)	Advanced melanoma	Exclude	\$515,000	0	No EBRx Restrictions to Exclude
4	Cell	Aucatzyl (obecabtagene autoleucel)	Relapsed/refractory B-cell Acute lymphoblastic leukemia (B-ALL)	Exclude	\$430,000	0	No EBRx Restrictions to Exclude
5	Gene	Beqvez (fidanacogene elaparvovec)	Hemophilia B	Exclude	\$2.5M	0	
6	Cell	Breyanzi (lisocabtagene maraleucel)	Relapsed/refractory large B-cell lymphoma (LBCL)	Exclude	\$410,300	0	No EBRx Restrictions to Exclude
7	Cell	Carvykti (ciltacabtagene autoleucel)	Relapsed/refractory multiple myeloma	Exclude	\$465,000	0	No EBRx Restrictions to Exclude
8	Gene	Casgevy (exagamglogene autotemcel or exa-cel)	Sickle cell disease; transfusion-dependent Beta thalassemia	Exclude	\$2.2M	0	
9	Gene	Elevidys (delandistrogene moxeparvovec-rokl)	Duchenne muscular dystrophy	Exclude	\$3.2M	0	
10	Gene	Hemgenix (etranacogene dezaparvovec-drlb)	Hemophilia B	Exclude	\$3.5M	0	No EBRx Restrictions to Exclude

11	Gene	Imlygic (talimogene laherparepvec)	Unresectable cutaneous, subcutaneous melanoma lesions	Exclude	\$70,000 per course	0	
12	Gene	Itvisma (onasemnogene abeparvovec-brve)	Spinal muscular atrophy (SMA)	Exclude	\$2.125M	0	No EBRx Restrictions to Exclude
13	Gene	Keblidi (eladocogene exuparvovec-tneq)	AADC deficiency	Exclude	\$3M	0	
14	Cell	Kymriah (tisagenlecleucel)	B-ALL and DLBCL	Exclude	\$373,000	0	No EBRx Restrictions to Exclude
15	Gene	Lenmeldy (atidarsagene autotemcel)	Metachromatic leukodystrophy (MLD)	Exclude	\$4.25M	0	
16	Gene	Luxturna (voretigene neparvovec-rzyl)	Inherited retinal dystrophy	Exclude	\$850,000	0	No EBRx Restrictions to Exclude
17	Cell	Lyfgenia (lovotibeglogene autotemcel or lovo-cel)	Sickle cell disease	Exclude	\$3.1M	0	
18	Cell	Omisirge (omidubicel-onlv)	Hematologic malignancies requiring allogeneic transplant	Exclude	\$330,000	0	
19	Gene	Papzimeos (zopapogene imadenovec-drba)	Recurrent respiratory papillomatosis	Exclude	\$2M	0	No EBRx Restrictions to Exclude
20	Cell	Provenge (sipuleucel-T)	Metastatic castration-resistant prostate cancer	Exclude	\$93,000	0	EBRx PA to Exclude
21	Gene	Roctavian (valoctocogene roxaparvovec-rvox)	Severe hemophilia A	Exclude	\$2.9M	0	
22	Cell	Skysona (elivaldogene autotemcel)	Cerebral adrenoleukodystrophy (CALD)	Exclude	\$3.0M	0	
23	Cell	Tecartus (brexucabtagene autoleucel)	Mantle cell lymphoma; adult B-ALL	Exclude	\$373,000	0	No EBRx Restrictions to Exclude
24	Cell	Tecelra (afamitresgene autoleucel)	Synovial sarcoma	Exclude	\$450,000	0	

25	Gene	Vyjuvek (beremagene geperpavec-svdt)	Dystrophic epidermolysis bullosa	Exclude	\$700,000 per year	0	
26	Gene	Waskyra (etuvetidigene autotemcel)	Wiskott-Aldrich syndrome	Exclude	\$3.5M	0	No EBRx Restrictions to Exclude
27	Cell	Yescarta (axicabtagene ciloleucel)	Large B-cell lymphoma	Exclude	\$373,000	0	No EBRx Restrictions to Exclude
28	Gene	Zevaskyn (prademagene zamikeracel)	Recessive dystrophic epidermolysis bullosa	Exclude	\$2M	0	No EBRx Restrictions to Exclude
29	Gene	Zynteglo (betibeglogene autotemcel)	Transfusion dependent Beta thalassemia	Exclude	\$2.8M	0	No EBRx Restrictions to Exclude
30	Gene	Zongensma (onasemnogene abeparvovec-xioi)	Spinal muscular atrophy (SMA) in pediatric patients <2 years	Exclude	\$2.125M	0	EBRx PA to Exclude